Get the BLPH Research Report and
Also Receive Our Top Trades for 2017!

Bellerophon Therapeutics, Inc.

On May 15, 2017, Bellerophon Therapeutics Inc., a clinical-stage biotherapeutics company, provided a business update and reported financial results for the first quarter ended March 31, 2017. The U.S. Food and Drug Administration (FDA) accepted modifications proposed by the Company to its Phase 3 program for INOpulse┬« in the treatment of PAH. Under the newly modified accelerated Phase 3 program, the INOvation-1 study, together with a second confirmatory randomized withdrawal study can serve as t … (See Research Report)
Download Research Report
on BLPH Now